Table 4.

Reduced HCC recurrence in patients on antiviral therapy.

Pts	Year Dx	Age	Sex	Tumor size (cm)	Child-pugh class	Initial tumor ablation	Anti-HBV therapy	Recurrence in months	Retreatment	Survival in months	Status
1	2000	57	M	2.5 Rt	A	RFA	LAM + TDF	None	None	152	Alive
2	2000	64	F	2.5 Rt	A	RFA	LAM + TDF	Residual	TACE	151	Alive
3	2001	49	M	4.0 Rt	A	Resection	LAM + TDF	None	None	140	Alive
4	2003	59	M	1.7 Rt	A	PCEI	LAM + ADV	None1	None	116	Alive
5	2003	50	M	2.5 Rt	B	Resection + RFA	LAM + TDF	None	None	116	Alive
6	2003	41	M	2.0 Rt	A	RFA	LAM + TDF	None	None	116	Alive
7	2004	60	M	3.4 Rt	A	TACE + RFA	LAM	None	None	104	Alive
8	2004	55	M	4.6 Rt	A	TACE	LAM + TDF	5 × 4 cm at 6 months	Lap-RFA chemo	15	Dead
9	2005	57	M	3.2 Rt	A	RFA, resection	LAM + ADV	None	None	94	Alive
10	2006	67	M	1.0 Rt	A	RFA	LAM + TDF	None	None	88	Alive
11	2007	20	F	2.8 Rt	A	RFA + TACE	TLV + TDF	None	None	65	Alive
12	2008	73	M	7.0 Rt	B	TACE x2, PCEI, RFA	LAM + TDF	Residual	None	57	Alive
131	2008	65	M	2.3 Rt	A	TACE	LAM + ADV	None	None	50	Dead
14	2009	51	M	4.0 Rt	A	TACE	TLV + TDF	None	None	50	Alive
15	2009	53	M	3.0 Rt	A	TACEx2	TDF	None	None	38	Alive
16	2010	66	M	1.4 Rt	A	TACE	TDF	None	None	26	Alive

HCC, hepatocellular carcinoma; RFA, radiofrequency ablation; LAM, lamivudine; TDF, tenofovir disoproxil fumarate; PCEI, percutaneous ethanol injection; ADV, adefovir dipivoxil; TACE, transarterial chemoembolization; Lap, laparoscopic; TLV, telbivudine.

¹Pt (no. 4) following successful PCEI ablation of Rt lobe HCC remained tumor-free for 7 years. During his trip abroad, he ran out of medicine for 3 weeks. Restarted antiviral drugs. Three months later, on a follow-up visit MRI, a new 6 mm lesion was detected at different site (Lt lobe) of the liver. At 3-month follow-up, the lesion grew to 1 cm and it was TACE'd. Pt (no. 4) is tumor-free for 4 years since and is on antiviral therapy.